Takeda Submits A New Drug Application In The U.S. For Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) For The Treatment Of Type 2 Diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of alogliptin (SYR-322) and ACTOS(R) (pioglitazone HCl) (”alogliptin/ACTOS”) in a single tablet for the treatment of type 2 diabetes.

More: continued here

Filed under: Clinical Trials on September 30th, 2008